ストックスクリーナーアプリを入手
4.82
4.37%
-0.22
アフターアワーズ：
4.85
0.03
+0.62%
前日終値:
$5.04
開ける：
$4.94
24時間の取引高:
999.74K
Relative Volume:
0.97
時価総額：
$311.84M
収益：
$500
当期純損益:
$-54.44M
株価収益率:
-4.1345
EPS:
-1.1658
ネットキャッシュフロー:
$-49.91M
1週間 パフォーマンス:
-3.41%
1か月 パフォーマンス:
+9.55%
6か月 パフォーマンス:
-6.77%
1年 パフォーマンス:
-11.72%
1日の値動き範囲:
$4.805
$5.00
1週間の範囲:
$4.80
$5.1049
52週間の値動き範囲:
$3.86
$10.08
Immuneering Corp Stock (IMRX) Company Profile
名前
Immuneering Corp
セクター
電話
617-500-8080
住所
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
4.82 | 339.66M | 500 | -54.44M | -49.91M | -1.1658 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-31 | 開始されました | Leerink Partners | Outperform |
| 2024-12-13 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | ダウングレード | Jefferies | Buy → Hold |
| 2024-03-15 | 繰り返されました | Needham | Buy |
| 2024-03-15 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | 開始されました | Needham | Buy |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-04-19 | アップグレード | Mizuho | Neutral → Buy |
| 2023-04-19 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | 開始されました | Mizuho | Neutral |
| 2023-02-03 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | 開始されました | Chardan Capital Markets | Buy |
| 2022-04-01 | 開始されました | Oppenheimer | Outperform |
| 2022-01-07 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Immuneering Corp (IMRX) 最新ニュース
H.C. Wainwright reiterates Immuneering stock rating on MEK pathway potential - Investing.com India
Immuneering comments on FDA pancreatic cancer drug approval By Investing.com - Investing.com India
Immuneering Highlights FDA Approval in Second-Line Pancreatic Cancer as Phase 3 MAPKeeper 301 Enrolls First-Line Patients - Quiver Quantitative
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients - Barchart.com
FDA approves a new pancreatic cancer treatment as Immuneering tests a first-line option - Stock Titan
Immuneering Corporation (NASDAQ:IMRX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff? - Stocktwits
Immuneering Stock Price Forecast. Should You Buy IMRX? - StockInvest.us
HC Wainwright Estimates Immuneering Q3 Earnings - MarketBeat
Immuneering Corp (IMRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immuneering (NASDAQ:IMRX) Now Covered by HC Wainwright - MarketBeat
Immuneering (NASDAQ:IMRX) Rating Increased to Strong-Buy at Chardan Capital - MarketBeat
H.C. Wainwright initiates Immuneering stock coverage with buy rating - Investing.com
H.C. Wainwright initiates Immuneering stock coverage with buy rating By Investing.com - Investing.com India
Immuneering (NASDAQ:IMRX) Releases Earnings Results - MarketBeat
Immuneering Corp 2026: Revenue ($17.44M), Net income ($17.27M), EPS ($0.27) — 10-Q Summary - TradingView
Immuneering Q2 Loss Widens as Cash Runway Extends Into 2029 - Quiver Quantitative
Immuneering reports Q2 2026 net loss $17.3M, cash $182.7M with runway into 2029 - TradingView
Immuneering Reports 17.3-Month Median Overall Survival in First-Line Pancreatic Cancer and Progresses Phase 3 MAPKeeper 301 Trial - quiverquant.com
Immuneering Corporation Q2 Net Income USD -17 - moomoo.com
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates - Barchart.com
Immuneering Corp (IMRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IMRX|Immuneering Corp|Price:4.165|Chg%:+0.035 - TradingKey
Immuneering Corp (IMRX) Income Statement - TradingKey
Immuneering Corp (IMRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immuneering Corp (IMRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immuneering Corp (IMRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immuneering Corp (IMRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immuneering Corp (IMRX) Institutional Confidence - TradingKey
IMRX|Immuneering Corp|Price:4.355|Chg%:+0.035 - TradingKey
Immuneering Corp (IMRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immuneering Corp (IMRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Immuneering Corp (IMRX) Cash Flow - TradingKey
Stock Ratings | Morgan Stanley raised its target price for Intel (INTC) to $75; Maxim Group initiated coverage on Rein Therapeutics (RNTX) with a target price of $4, representing a potential gain of 373.93%. - Sahm
Immuneering Corporation (IMRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Immuneering reports preclinical data on atebimetinib in journal - Investing.com
IMRX Maintains by Needham -- Price Target Raised to $18.00 - GuruFocus
Immuneering (NASDAQ:IMRX) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Immuneering Corporation Announces Grants of Inducement Awards - The Manila Times
Form 4 Immuneering Corp For: 17 July By Investing.com - Investing.com Nigeria
IMRX News | IMMUNEERING CORPCLASS A (NASDAQ:IMRX) - ChartMill
Immuneering (IMRX) awards CFO Andrew Gengos 650,000 stock options - Stock Titan
Immuneering Corporation Announces Inducement Equity Grants to New CFO and Employee - Quiver Quantitative
Immuneering’s New CFO Gets 650,000-Share Option With $4.78 Exercise Price - Stock Titan
Immuneering (IMRX) Dips 2.93% as Resistance Holds FirmSeasonality Effect - vinanet.vn
Immuneering Corp (IMRX) CFO discloses 225,000 Class A shares - Stock Titan
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Cantor Fitzgerald initiates Immuneering stock with overweight rating - Investing.com
If You Invested $1,000 in Immuneering Corp (IMRX) - Stock Titan
IMRXImmuneering Corp Latest SEC Filings - Finviz
Immuneering Corp (IMRX) 財務データ
収益
当期純利益
現金流量
EPS
Immuneering Corp (IMRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER |
Jun 15 '26 |
Buy |
4.15 |
6,035 |
25,045 |
382,531 |
| Brakewood Harold Eugene | Chief Business Officer |
Jan 16 '26 |
Buy |
4.76 |
5,250 |
24,990 |
11,050 |
| Schall Thomas J. | Director |
Jan 15 '26 |
Buy |
4.67 |
21,645 |
101,041 |
74,530 |
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER |
Jan 15 '26 |
Buy |
4.57 |
2,298 |
10,502 |
376,496 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER |
Jan 13 '26 |
Buy |
4.15 |
2,626 |
10,906 |
25,970 |
| Feinberg Peter | Director |
Jan 12 '26 |
Buy |
4.35 |
20,000 |
86,904 |
135,441 |
| Feinberg Peter | Director |
Oct 03 '25 |
Buy |
6.67 |
7,500 |
50,025 |
156,766 |
| Morales Mallory | Chief Accounting Officer |
Oct 01 '25 |
Buy |
6.39 |
300 |
1,917 |
27,533 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER |
Oct 01 '25 |
Buy |
6.38 |
800 |
5,103 |
23,344 |
| Bookman Michael | CHIEF LEGAL OFFICER, SECRETARY |
Oct 01 '25 |
Buy |
6.83 |
1,020 |
6,966 |
4,870 |
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):